Reports

Global Cardiac Biomarkers Market Analysis, Trends, Growth: By Biomarker Type: Creatine Kinase -MB (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia Modified Albumin (IMA), Others; By Indication; By End User; By Testing Location; Regional Analysis; Competitive Landscape; 2024-2032

Global Cardiac Biomarkers Market Outlook

The global cardiac biomarkers market reached a value of about USD 9.4 billion in 2021. The market is further estimated to grow at a CAGR of 9.90% in the forecast period of 2024-2032 to reach a value of around USD 15.07 billion by 2027.

cardiac biomarkers market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Expanding Point of Care Testing Facility to Propel the Market Growth of Cardiac Biomarkers

Based on testing location, the point of care segment is expected to witness robust growth in the market of cardiac biomarkers over the forecast period. This could be attributed to the rising inclination towards point of care testing due to its potential to offer high sensitivity diagnosis. The improved patient management owing to rapid turnaround of results in a user-friendly manner without wasting time is accelerating the development of the market. The point of care offers high-quality biomarker measurements for diverse clinical settings, including acute care, outpatient clinics, clinical research centres, homes, rural areas, and the developing world. The point of care testing facilitates rapid treatment decisions and reduces the pressure on emergency departments. They enable widespread access to affordable cardiac diagnostics as it leads to reduction in overall hospital and laboratory facility costs.

Market Segmentation

cardiac biomarkers market by segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Cardiac biomarkers are used to diagnose critical heart conditions by evaluating the heart functioning of a patient. The biomarkers include enzymes, hormones or proteins that show up in the blood under severe stress or any injury and the test measure these cardiac biomarkers to find the seriousness of heart disease.

The market for cardiac biomarkers, by biomarker type, is divided into:

Creatine Kinase -MB (CK-MB)
Troponins (T and I)
Myoglobin
Brain Natriuretic Peptide (BNPs) or NT-proBNP
Ischemia Modified Albumin (IMA)
Others

Based on indication, the market is segmented into:

Myocardial Infarction
Congestive Heart Failure
Acute Coronary Syndrome
Atherosclerosis
Others

On the basis of end-user, the market is bifurcated into:

Hospitals
Speciality Clinics

Based on testing location, the market is divided into:

Point of Care
Laboratory Testing

cardiac biomarkers market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

The regional markets for cardiac biomarkers can be divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Increasing Prevalence of Critical Heart Conditions to Drive the Market Growth of Cardiac Biomarkers

The pandemic bolstered the market for cardiac biomarkers due to the impact of COVID 19 on cardiovascular systems, which led to the rising application of biomarkers in diagnosis and treatment. The increasing cases of cardiac diseases worldwide due to unhealthy lifestyle changes are providing impetus to the market development of cardiac biomarkers. As per the World Health Organisation estimates, approximately 17.9 million people died from cardiovascular diseases in 2019, representing 32% of overall global deaths. The growing awareness about the reliable diagnosis that cardiac biomarkers offer to prevent heart diseases and the developing healthcare infrastructure play a critical role in expanding the market of cardiac biomarkers. The government initiatives to improve the diagnosis and treatment of cardiovascular diseases and the rising approvals of biomarker tests by organisations like the United States Food and Drug Administration is also invigorating the market of cardiac biomarkers. The increasing diagnostic tests offered by market players and the rapid development of novel biomarker tests to support clinicians in cardiac risk identification are expected to augment the market over the forecast period.

Key Players in the Global Cardiac Biomarkers Market

The report gives a detailed analysis of the following key players in the global cardiac biomarkers market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

F. Hoffmann-La Roche Ltd
Beckman Coulter, Inc.
Creative Diagnostics
Bio-Rad Laboratories, Inc.
bioMérieux SA
Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

Key Highlights of the Report

REPORT FEATURES	DETAILS
Base Year	2023
Historical Period	2018-2023
Forecast Period	2024-2032
Scope of the Report	Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment: Biomarker Type Indication End User Testing Location Region
Breakup by Biomarker Type	Creatine Kinase -MB (CK-MB) Troponins (T and I) Myoglobin Brain Natriuretic Peptide (BNPs) or NT-proBNP Ischemia Modified Albumin (IMA) Others
Breakup by Indication	Myocardial Infarction Congestive Heart Failure Acute Coronary Syndrome Atherosclerosis Others
Breakup by End User	Hospitals Speciality Clinics
Breakup by Testing Location	Point of Care Laboratory Testing
Breakup by Region	North America United States of America Canada Europe United Kingdom Germany France Italy Others Asia Pacific China Japan India ASEAN Australia Others Latin America Brazil Argentina Mexico Others Middle East and Africa Saudi Arabia United Arab Emirates Nigeria South Africa Others
Market Dynamics	SWOT Porter's Five Forces Key Indicators for Demand Key Indicators for Price
Competitive Landscape	Market Structure Company Profiles Company Overview Product Portfolio Demographic Reach and Achievements Certifications
Companies Covered	F. Hoffmann-La Roche Ltd Beckman Coulter, Inc. Creative Diagnostics Bio-Rad Laboratories, Inc. bioMérieux SA Others
Report Price and Purchase Option	Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format	Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1   Preface
2   Report Coverage – Key Segmentation and Scope
3   Report Description
   3.1   Market Definition and Outlook
   3.2   Properties and Applications
   3.3   Market Analysis
   3.4   Key Players
4   Key Assumptions
5   Executive Summary
   5.1   Overview
   5.2   Key Drivers
   5.3   Key Developments
   5.4   Competitive Structure
   5.5   Key Industrial Trends
6   Market Snapshot
   6.1   Global
   6.2   Region
7   Opportunities and Challenges in the Market
8   Global Cardiac Biomarkers Market Analysis
   8.1   Key Industry Highlights
   8.2   Global Cardiac Biomarkers Historical Market (2018-2023)
   8.3   Global Cardiac Biomarkers Market Forecast (2024-2032)
   8.4   Global Cardiac Biomarkers Market by Biomarker Type
       8.4.1   Creatine Kinase -MB (CK-MB)
8.4.1.1   Historical Trend (2018-2023)
           8.4.1.2 Forecast Trend (2024-2032)
       8.4.2   Troponins (T and I)
8.4.2.1 Historical Trend (2018-2023)
           8.4.2.2 Forecast Trend (2024-2032)
       8.4.3   Myoglobin
8.4.3.1 Historical Trend (2018-2023)
           8.4.3.2 Forecast Trend (2024-2032)
       8.4.4   Brain Natriuretic Peptide (BNPs) or NT-proBNP
8.4.4.1 Historical Trend (2018-2023)
           8.4.4.2 Forecast Trend (2024-2032)
       8.4.5   Ischemia Modified Albumin (IMA)
8.4.5.1 Historical Trend (2018-2023)
           8.4.5.2 Forecast Trend (2024-2032)
       8.4.6   Others
   8.5   Global Cardiac Biomarkers Market by Indication
       8.5.1   Myocardial Infarction
8.5.1.1 Historical Trend (2018-2023)
           8.5.1.2 Forecast Trend (2024-2032)
       8.5.2   Congestive Heart Failure
8.5.2.1 Historical Trend (2018-2023)
           8.5.2.2 Forecast Trend (2024-2032)
       8.5.3   Acute Coronary Syndrome
8.5.3.1 Historical Trend (2018-2023)
           8.5.3.2 Forecast Trend (2024-2032)
       8.5.4   Atherosclerosis
8.5.4.1 Historical Trend (2018-2023)
           8.5.4.2 Forecast Trend (2024-2032)
       8.5.5   Others
   8.6   Global Cardiac Biomarkers Market by End User
       8.6.1   Hospitals
8.6.1.1 Historical Trend (2018-2023)
           8.6.1.2 Forecast Trend (2024-2032)
       8.6.2   Speciality Clinics
8.6.2.1 Historical Trend (2018-2023)
           8.6.2.2 Forecast Trend (2024-2032)
   8.7   Global Cardiac Biomarkers Market by Testing Location
       8.7.1   Point of Care
8.7.1.1 Historical Trend (2018-2023)
           8.7.1.2 Forecast Trend (2024-2032)
       8.7.2   Laboratory Testing
8.7.2.1 Historical Trend (2018-2023)
           8.7.2.2 Forecast Trend (2024-2032)
   8.8 Global Cardiac Biomarkers Market by Region
        8.8.1    North America
            8.8.1.1    Historical Trend (2018-2023)
            8.8.1.2    Forecast Trend (2024-2032)
        8.8.2    Europe
            8.8.2.1    Historical Trend (2018-2023)
            8.8.2.2    Forecast Trend (2024-2032)
        8.8.3    Asia Pacific
            8.8.3.1    Historical Trend (2018-2023)
            8.8.3.2    Forecast Trend (2024-2032)
        8.8.4    Latin America
            8.8.4.1    Historical Trend (2018-2023)
            8.8.4.2    Forecast Trend (2024-2032)
        8.8.5    Middle East and Africa
            8.8.5.1    Historical Trend (2018-2023)
            8.8.5.2    Forecast Trend (2024-2032)
9    North America Cardiac Biomarkers Market Analysis
    9.1    United States of America
        9.1.1    Historical Trend (2018-2023)
        9.1.2    Forecast Trend (2024-2032)
    9.2    Canada
        9.2.1    Historical Trend (2018-2023)
        9.2.2    Forecast Trend (2024-2032)
10    Europe Cardiac Biomarkers Market Analysis
    10.1    United Kingdom
        10.1.1    Historical Trend (2018-2023)
        10.1.2    Forecast Trend (2024-2032)
    10.2    Germany
        10.2.1    Historical Trend (2018-2023)
        10.2.2    Forecast Trend (2024-2032)
    10.3    France
        10.3.1    Historical Trend (2018-2023)
        10.3.2    Forecast Trend (2024-2032)
    10.4    Italy
        10.4.1    Historical Trend (2018-2023)
        10.4.2    Forecast Trend (2024-2032)
    10.5    Others
11    Asia Pacific Cardiac Biomarkers Market Analysis
    11.1    China
        11.1.1    Historical Trend (2018-2023)
        11.1.2    Forecast Trend (2024-2032)
    11.2    Japan
        11.2.1    Historical Trend (2018-2023)
        11.2.2    Forecast Trend (2024-2032)
    11.3    India
        11.3.1    Historical Trend (2018-2023)
        11.3.2    Forecast Trend (2024-2032)
    11.4    ASEAN
        11.4.1    Historical Trend (2018-2023)
        11.4.2    Forecast Trend (2024-2032)
    11.5    Australia
        11.5.2    Historical Trend (2018-2023)
        11.5.2    Forecast Trend (2024-2032)
    11.6    Others
12    Latin America Cardiac Biomarkers Market Analysis
    12.1    Brazil
        12.1.1    Historical Trend (2018-2023)
        12.1.2    Forecast Trend (2024-2032)
    12.2    Argentina
        12.2.1    Historical Trend (2018-2023)
        12.2.2    Forecast Trend (2024-2032)
    12.3    Mexico
        12.3.1    Historical Trend (2018-2023)
        12.3.2    Forecast Trend (2024-2032)
    12.4    Others
13    Middle East and Africa Cardiac Biomarkers Market Analysis
    13.1    Saudi Arabia
        13.1.1    Historical Trend (2018-2023)
        13.1.2    Forecast Trend (2024-2032)
    13.2    United Arab Emirates
        13.2.1    Historical Trend (2018-2023)
        13.2.2    Forecast Trend (2024-2032)
    13.3    Nigeria
        13.3.1    Historical Trend (2018-2023)
        13.3.2    Forecast Trend (2024-2032)
    13.4    South Africa
        13.4.1    Historical Trend (2018-2023)
        13.4.2    Forecast Trend (2024-2032)
    13.5    Others
14    Market Dynamics
    14.1    SWOT Analysis
        14.1.1    Strengths
        14.1.2    Weaknesses
        14.1.3    Opportunities
        14.1.4    Threats
    14.2    Porter’s Five Forces Analysis
        14.2.1    Supplier’s Power
        14.2.2    Buyer’s Power
        14.2.3    Threat of New Entrants
        14.2.4    Degree of Rivalry
        14.2.5    Threat of Substitutes
    14.3    Key Indicators for Demand
    14.4    Key Indicators for Price
15    Value Chain Analysis
16    Competitive Landscape
    16.1    Market Structure
    16.2    Company Profiles
        16.2.1    F. Hoffmann-La Roche Ltd
            16.2.1.1    Company Overview
            16.2.1.2    Product Portfolio
            16.2.1.3    Demographic Reach and Achievements
            16.2.1.4    Certifications
        16.2.2    Beckman Coulter, Inc.
            16.2.2.1    Company Overview
            16.2.2.2    Product Portfolio
            16.2.2.3    Demographic Reach and Achievements
            16.2.2.4    Certifications
        16.2.3    Creative Diagnostics
            16.2.3.1    Company Overview
            16.2.3.2    Product Portfolio
            16.2.3.3    Demographic Reach and Achievements
            16.2.3.4    Certifications
        16.2.4    Bio-Rad Laboratories, Inc.
            16.2.4.1    Company Overview
            16.2.4.2    Product Portfolio
            16.2.4.3    Demographic Reach and Achievements
            16.2.4.4    Certifications
        16.2.5    bioMérieux SA
            16.2.5.1    Company Overview
            16.2.5.2    Product Portfolio
            16.2.5.3    Demographic Reach and Achievements
            16.2.5.4    Certifications
        16.2.6    Others
17    Key Trends and Developments in the Market

List of Key Figures and Tables

1.   Global Cardiac Biomarkers Market: Key Industry Highlights, 2018 and 2032
2.   Global Cardiac Biomarkers Historical Market: Breakup by Biomarker Type (USD Billion), 2018-2023
3.   Global Cardiac Biomarkers Market Forecast: Breakup by Biomarker Type (USD Billion), 2024-2032
4.   Global Cardiac Biomarkers Historical Market: Breakup by Indication (USD Billion), 2018-2023
5.   Global Cardiac Biomarkers Market Forecast: Breakup by Indication (USD Billion), 2024-2032
6.   Global Cardiac Biomarkers Historical Market: Breakup by End-User (USD Billion), 2018-2023
7.   Global Cardiac Biomarkers Market Forecast: Breakup by End-User (USD Billion), 2024-2032
8.   Global Cardiac Biomarkers Historical Market: Breakup by Testing Location (USD Billion), 2018-2023
9.   Global Cardiac Biomarkers Market Forecast: Breakup by Testing Location (USD Billion), 2024-2032
10.   Global Cardiac Biomarkers Historical Market: Breakup by Region (USD Billion), 2018-2023
11.   Global Cardiac Biomarkers Market Forecast: Breakup by Region (USD Billion), 2024-2032
12.   North America Cardiac Biomarkers Historical Market: Breakup by Country (USD Billion), 2018-2023
13.   North America Cardiac Biomarkers Market Forecast: Breakup by Country (USD Billion), 2024-2032
14.   Europe Cardiac Biomarkers Historical Market: Breakup by Country (USD Billion), 2018-2023
15.   Europe Cardiac Biomarkers Market Forecast: Breakup by Country (USD Billion), 2024-2032
16.   Asia Pacific Cardiac Biomarkers Historical Market: Breakup by Country (USD Billion), 2018-2023
17.   Asia Pacific Cardiac Biomarkers Market Forecast: Breakup by Country (USD Billion), 2024-2032
18.   Latin America Cardiac Biomarkers Historical Market: Breakup by Country (USD Billion), 2018-2023
19.   Latin America Cardiac Biomarkers Market Forecast: Breakup by Country (USD Billion), 2024-2032
20.   Middle East and Africa Cardiac Biomarkers Historical Market: Breakup by Country (USD Billion), 2018-2023
21.   Middle East and Africa Cardiac Biomarkers Market Forecast: Breakup by Country (USD Billion), 2024-2032
22.   Global Cardiac Biomarkers Market Structure.

Key Questions Answered in the Report

What was the global cardiac biomarkers market size in 2021?

In 2021, the global cardiac biomarkers market attained a value of nearly USD 9.4 billion.

What is the growth rate of the market?

The market is assessed to grow at a CAGR of 9.90% between 2024 and 2032.

What is the forecast outlook of the market for 2024-2032?

The market is estimated to witness a healthy growth in the forecast period of 2024-2032 to reach almost USD 15.07 billion by 2027.

What are the major market drivers?

The major market drivers include the rising importance of cardiac biomarkers in treating heart diseases, developing healthcare infrastructure, and the expansion of point of care facilities.

What are the key market trends of the global cardiac biomarkers market?

The key market trends guiding the growth of the market include the increasing cases of heart diseases, government initiatives in approving the biomarker diagnostic tests, and development of novel cardiac biomarker tests by market players.

What are the major regional markets of cardiac biomarkers, according to the EMR report?

The major regions in the market are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

What are the significant biomarker types of cardiac biomarkers?

The significant biomarker types of cardiac biomarkers include Creatine Kinase -MB (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, and Ischemia Modified Albumin (IMA), among others.

What are the various indications of the market?

The various indications of the market, include myocardial infarction, congestive heart failure, acute coronary syndrome, and atherosclerosis, among others.

What are the major end users of the market?

The major end users of the market include hospitals and speciality clinics.

What are the different testing locations of cardiac biomarkers?

The different testing locations of cardiac biomarkers, include point of care and laboratory testing.

Who are the key market players, according to the report?

The major players in the market are F. Hoffmann-La Roche Ltd, Beckman Coulter, Inc., Creative Diagnostics, Bio-Rad Laboratories, Inc., and bioMérieux SA, among others.

Analyst Review

The global cardiac biomarkers market attained a value of nearly USD 9.4 billion in 2021, driven by the increasing cases of critical heart conditions. Aided by the development of cardiac biomarker tests by market players, the market is expected to witness a further growth in the forecast period of 2024-2032, growing at a CAGR of 9.90%. The market is estimated to reach about USD 15.07 billion by 2027.

EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. The market for cardiac biomarkers, by biomarker type, is divided into Creatine Kinase -MB (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, and Ischemia Modified Albumin (IMA), among others. Based on indication, the market is segmented into myocardial infarction, congestive heart failure, acute coronary syndrome, and atherosclerosis, among others. On the basis of end user, the market is classified into hospitals and speciality clinics. Based on testing location, the market is bifurcated into point of care and laboratory testing. The major regional markets for cardiac biomarkers are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include F. Hoffmann-La Roche Ltd, Beckman Coulter, Inc., Creative Diagnostics, Bio-Rad Laboratories, Inc., and bioMérieux SA, among others.

EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.

Request Sample

Purchase Full Report

Mini Report

$1699

Selected Sections, One User
Printing Not Allowed
Email Delivery in PDF
~~Free Limited Customisation~~
~~Post Sales Analyst Support~~
~~50% Discount on Next Update~~

Buy Now

Single User License

$2799

All Sections, One User
One Print Allowed
Email Delivery in PDF
~~Free Limited Customisation~~
~~Post Sales Analyst Support~~
~~50% Discount on Next Update~~

Buy Now

Five User License

$3999

All Sections, Five Users
Five Prints Allowed
Email Delivery in PDF
Free Limited Customisation
Post Sales Analyst Support
~~50% Discount on Next Update~~

Buy Now

Corporate License

$4999

All Sections, Unlimited Users
Unlimited Prints Allowed
Email Delivery in PDF + Excel
Free Limited Customisation
Post Sales Analyst Support
50% Discount on Next Update

Buy Now

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation

Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER